Organ transplantation

Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale

Retrieved on: 
Friday, August 18, 2023
Biotechnology, Other Health, Diabetes, Health, General Health, Medical Devices, Research, Infectious Diseases, Surgery, Science, Clinical Trials, Inc., GMP, DTC, Stiff-person syndrome, DNA, Allergy, Pharyngealization, Mayo Clinic, Central nervous system, Therapy, Life, Clinical trial, Genetics, STI, Marketing, Urinary tract infection, Genomics, Safety, COVID-19, Direct-to-consumer advertising, Point of care, Favipiravir, CTA, Infection, E-commerce, Autoimmunity, Psoriasis, Nature, RSV, Acquisition, Patient, Organ transplantation, Immune system, Medicine, Viral, Entrepreneurship, Clinical professor, Neurology, Skin, Social media, Software, Vaccine, Pharmaceutical industry, T1D

For Q2 2023 and the first half of the Q3 2023, we have been heavily focused on ongoing conversations around promising innovations.

Key Points: 
  • For Q2 2023 and the first half of the Q3 2023, we have been heavily focused on ongoing conversations around promising innovations.
  • We also mutually agreed to terminate the non-binding letter of intent with Natural State Genomics and Natural State Laboratories.
  • Since the founding of Aditxt, we have believed that commercializing health innovations deserves a new approach driven by stakeholders.
  • Continuing to expand product pipeline, research, and development, and have wider commercial reach with patients with a POC testing platform.

TransMedics Completes Acquisition of Summit Aviation

Retrieved on: 
Wednesday, August 16, 2023
Heart, Transmedicalism, Aviation, Freedom Air, Summit Air, Oklahoma City Air Logistics Complex, Acquisition, NOP, MD, Patient, Organ transplantation, Liver failure, Summit, Medical imaging, Management, Airline

ANDOVER, Mass., Aug. 16, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the closing of its previously announced acquisition of Summit Aviation, a premier U.S. charter flight operator.

Key Points: 
  • ANDOVER, Mass., Aug. 16, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the closing of its previously announced acquisition of Summit Aviation, a premier U.S. charter flight operator.
  • The acquisition enables the establishment of TransMedics Aviation as the first integrated national provider of air logistics dedicated exclusively to organ transplantation in the U.S.
    "We are delighted to complete the acquisition of Summit Aviation, which represents a critical element of TransMedics' strategy to build and manage a national transplant logistics network designed to expand the reach and coverage of the National OCS Program (NOP)," said Waleed Hassanein, MD, President and Chief Executive Officer.
  • "I want to take this opportunity to welcome the Summit team to the TransMedics team.
  • I also want to welcome Ben Walton in his new role as our new VP of Aviation Services."

Pieces Technologies Achieves a Major Milestone: 1 Million Autonomously Written Inpatient Clinical Summaries

Retrieved on: 
Wednesday, August 9, 2023
NIST, Communication, Houston Methodist Hospital, Internal medicine, Hallucination, Case management (US healthcare system), Pediatrics, Synthetic media, Hospital, MD, Patient, Length of stay, Nursing, Organ transplantation, Generative, AI, Intensive care unit, Houston Methodist Sugar Land Hospital, Roger Hawkins (drummer), Safety, Software, Medical device, DALLAS, Piece

Pieces reached the milestone within 7 months of going live, and with an industry leading "severe hallucination rate" of less than 0.1%.

Key Points: 
  • Pieces reached the milestone within 7 months of going live, and with an industry leading "severe hallucination rate" of less than 0.1%.
  • Pieces AI generates 1M autonomously written clinical summaries in real-world inpatient settings, a U.S. first.
  • "Self-drafting 1 million summaries that doctors and nurses can – and have – relied upon in real-time is perhaps Pieces' most significant clinical and technical accomplishment in 7 years" says Ruben Amarasingham, MD, CEO of Pieces.
  • We are on track to achieve a severe hallucination rate of less than 1 error in 1 million summaries generated."

Qihan Biotech Appoints Naxin Yao to its Board of Directors

Retrieved on: 
Friday, July 28, 2023
Stem Cells, Other Science, Research, General Health, Other Health, Surgery, Pharmaceutical, Oncology, Publishing, Public Relations, Investor Relations, Marketing, Advertising, Communications, Biotechnology, Social Media, Search Engine Optimization, Search Engine Marketing, Health, Blogging, Science, University of California, Berkeley, Hangzhou, Business, Medicine, Shen Qihan, Strategic planning, Genetic engineering, Molecular biology, Entrepreneurship, Cell biology, UC, Patient, Organ transplantation, Peking University, Genetic, Stanford Graduate School of Business, Genome, Management, Pharmaceutical industry

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today the appointment of Mr. Naxin Yao, as an independent director to its Board of Directors.

Key Points: 
  • Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today the appointment of Mr. Naxin Yao, as an independent director to its Board of Directors.
  • "We warmly welcome Mr. Yao to join the Board of Directors of Qihan.
  • "I am honored to join the Board of Directors of Qihan Biotech and be part of a bright company driven by technology and innovation.
  • I believe that young scientists can showcase their talents to their full potential in Qihan and create products that cure diseases and save lives," said Mr. Yao.

NASP Thanks the Senate Finance Committee for Taking Initial Steps to Address Anticompetitive PBM Practices

Retrieved on: 
Thursday, July 27, 2023
Senate, Pharmacy, DIR, City of London Finance Committee, Cancer, Haemophilia, Multiple sclerosis, Part, United States Senate Finance Subcommittee on Health Care, Medicare Part D, Committee, NASP, Medicare, Congress, PBM, Specialty pharmacy, Patient, Organ transplantation, Ranking, Cystic fibrosis, Growth, Rare, National Association, Committee on Finance, Rheumatoid arthritis, Hospital, Medicaid

Specialty pharmacies face low upfront reimbursement rates and growing clawbacks from some PBMs that surpass millions in dollars for many specialty pharmacies.

Key Points: 
  • Specialty pharmacies face low upfront reimbursement rates and growing clawbacks from some PBMs that surpass millions in dollars for many specialty pharmacies.
  • To address this, it is urgent the Finance Committee include the full bipartisan Protect Patient Access to Pharmacies Act (S. 2052) in the final PBM reform package the Committee advances this year.
  • During the mark up, Chairman Wyden expressed his support for continuing to work to address inclusion of this bill.
  • The Committee must act on S. 2052 this year as it finalizes its PBM reform efforts.

World Renowned Biomedical Professor Jonathan Lakey Joins CancerVAX Board of Advisors

Retrieved on: 
Thursday, July 27, 2023
Meritorious Service Medal (China), BS, Radiation, University, Royal college, Diabetes, Meritorious Service Medal, Physician, Edmonton protocol, Enzyme, University of California, Irvine, Cancer, Research, Central Waqf Council, Doctor of Philosophy, Biomedical engineering, MS, Patient, Organ transplantation, Surgeon, B cell, Transplant, Royal College of Physicians and Surgeons of Canada, Disease, Dentistry, Science, LEHI

Dr. Lakey graduated from the University of Alberta with a BS, MS and PhD and received post-doctoral training in Indianapolis and Seattle.

Key Points: 
  • Dr. Lakey graduated from the University of Alberta with a BS, MS and PhD and received post-doctoral training in Indianapolis and Seattle.
  • Dr. Lakey is currently the Professor of Surgery and Biomedical Engineering and the Director of the Clinical Islet Program at University of California Irvine.
  • CancerVAX CEO Ryan Davies said, “We are honored to have Dr. Lakey join our Board of Advisors.
  • This is a noble cause and I am honored to have a part in the exciting work CancerVAX is doing”, said Dr. Lakey.

Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND) Application for QN-019a, a Multi-locus Gene-Editing Cell Therapy Product to treat CD19-positive B-Cell Lymphoma

Retrieved on: 
Tuesday, July 18, 2023
Research, General Health, Oncology, Genetics, Publishing, Public Relations, Investor Relations, Clinical Trials, Science, Marketing, Biotechnology, Communications, Health, Cell, Clinical trial, NK, Shen Qihan, Patient, Organ transplantation, National Medical Products Administration, Center for Drug Evaluation and Research, IND, NMPA, Genome, Pharmaceutical industry

It is the first IND approved in China for a gene-edited iPSC-derived cell therapy product.

Key Points: 
  • It is the first IND approved in China for a gene-edited iPSC-derived cell therapy product.
  • Qihan Biotech utilizes multiplexable genome editing technology to modify human Induced Pluripotent Stem Cells (iPSCs) and differentiate them into natural killer (NK) cell therapy product QN-019a, targeting CD19-positive B-cell lymphoma.
  • According to the official website of the Center for Drug Evaluation, NMPA, the clinical trial application for QN-019a cell injection has received approval as of July 18, 2023.
  • "We look forward to developing Off-the-Shelf cell therapy products with long-term efficacy for patients and realizing the vision of Qihan.”

Devyser's NGS products for monitoring of kidney and stem cell transplanted patients receive IVDR approvals

Retrieved on: 
Monday, July 17, 2023
ESRD, Kidney transplantation, IVDR, NGS, Survival, Ageing, Thermo Fisher Scientific, Chronic kidney disease, Dialysis, Transplant, Incidence, Nephritis, Patient, Organ transplantation, Kidney, Conditional sentence, Kidney disease, Safety, Medical device, Dentistry, European

STOCKHOLM, July 17, 2023 /PRNewswire/ -- Devyser's novel test for detecting donor-derived cell-free DNA in blood samples from kidney-transplant patients and its product for screening and follow-up of stem cell transplanted patients fulfill IVDR requirements in Europe.

Key Points: 
  • STOCKHOLM, July 17, 2023 /PRNewswire/ -- Devyser's novel test for detecting donor-derived cell-free DNA in blood samples from kidney-transplant patients and its product for screening and follow-up of stem cell transplanted patients fulfill IVDR requirements in Europe.
  • Thermo Fisher Scientific, Devyser's commercialization partner for these products, can now market and sell the regulatory-approved products in all European markets, in accordance with their launch plans.
  • The IVDR approved products are One Lambda Devyser Chimerism, for early detection of mixed chimerism in stem cell transplanted patients, and One Lambda Devyser Accept cfDNA, a novel test for the detection of donor-derived cell-free DNA in blood samples from kidney transplant patients.
  • "Over the last two and half years, we have been working extensively in developing our products for post-transplant monitoring of stem cell transplanted and kidney transplanted patients.

Devyser's NGS products for monitoring of kidney and stem cell transplanted patients receive IVDR approvals

Retrieved on: 
Monday, July 17, 2023
ESRD, Kidney transplantation, IVDR, NGS, Survival, Ageing, Thermo Fisher Scientific, Chronic kidney disease, Dialysis, Transplant, Incidence, Nephritis, Patient, Organ transplantation, Kidney, Conditional sentence, Kidney disease, Safety, Medical device, Dentistry, European

STOCKHOLM, July 17, 2023 /PRNewswire/ -- Devyser's novel test for detecting donor-derived cell-free DNA in blood samples from kidney-transplant patients and its product for screening and follow-up of stem cell transplanted patients fulfill IVDR requirements in Europe.

Key Points: 
  • STOCKHOLM, July 17, 2023 /PRNewswire/ -- Devyser's novel test for detecting donor-derived cell-free DNA in blood samples from kidney-transplant patients and its product for screening and follow-up of stem cell transplanted patients fulfill IVDR requirements in Europe.
  • Thermo Fisher Scientific, Devyser's commercialization partner for these products, can now market and sell the regulatory-approved products in all European markets, in accordance with their launch plans.
  • The IVDR approved products are One Lambda Devyser Chimerism, for early detection of mixed chimerism in stem cell transplanted patients, and One Lambda Devyser Accept cfDNA, a novel test for the detection of donor-derived cell-free DNA in blood samples from kidney transplant patients.
  • "Over the last two and half years, we have been working extensively in developing our products for post-transplant monitoring of stem cell transplanted and kidney transplanted patients.

3D Cell Culture Market worth $2.5 billion | MarketsandMarkets

Retrieved on: 
Thursday, July 13, 2023
Differentiable function, Private sector, Corning Inc., Prevalence, Culture, Thermo Fisher Scientific, 3D, Cancer, Biomedical Research, Merck Group, Tissue engineering, Government, Regenerative medicine, Plasma, Incidence, Cancer stem cell, HIV disease progression rates, Organ transplantation, Drug discovery, Biology, Corning, Growth, ECM, 3D printing, Pharmaceutical industry, Video game, Fine chemical, Medical imaging, Retail

Scaffold-based 3D cell culture accounted for the largest share of the product segment in the 3D cell culture market in 2022.

Key Points: 
  • Scaffold-based 3D cell culture accounted for the largest share of the product segment in the 3D cell culture market in 2022.
  • Based on product, the 3D cell culture market is segmented into scaffold-based 3D cell cultures, scaffold-free 3D cell cultures, microfluidics-based 3D cell cultures, and magnetic & bioprinted 3D cell cultures.
  • 3D Cell Culture Market Dynamics:
    The 3D cell culture market is consolidated, with a small number of players competing for market shares.
  • Tracking product portfolios of prominent market players helps to analyze the major products in the 3D cell culture market.